Sorry for the inconvenience.

Chinese users are only allowed to visit websites which complies with the PIPL (Personal Information Protection Law of the People's Republic of China) effective November 1st.

▲ Scan or click the QR code to visit 三星医疗

The personal information of existing chinese users will be kept until October 29th and will be safely deleted thereafter.

Upgrade browser for full Samsung Healthcare experience

It looks like you may be using a web browser that we don’t support.
Make sure you’re using one of these recommended browsers,
or upgrade your browser by clicking the icons, to get the full Samsung Healthcare experience.

To check which browser you use
본문 바로가기


Experience the advances and contributions we have made

White Paper

Role of CrystalVue™ and MV-Flow™ with LumiFlow ™ in the prenatal diagnosis of Placenta Accreta Spectrum

  • #Ultrasound System>Womens Health
  • writerDeepa Srinivasan Andrea Dall’Asta Christoph Lees
  • date2022.01.03
Placenta accreta spectrum (PAS), previously known as abnormally invasive placenta (AIP), encompasses a group of disorders characterized by an abnormally deep invasion of the placental trophoblasts into the myometrium or into the organs surrounding the gravid uterus. The rising rate of cesarean section together with the increased maternal age and use of assisted reproductive techniques are accounted as major determinants of the increased frequency of PAS, which is currently reported to range between 1:300 and 1:2000 pregnancies. PAS is acknowledged to represent a major risk factor for pregnancy and peripartum complications including potentially life-threatening hemorrhage requiring emergency hysterectomy and blood transfusion. In such context, the antenatal characterization of the placental location and the risk of PAS has been demonstrated to improve multidisciplinary care management and surgical planning, ultimately leading to reduced maternal peripartum morbidity.